DK1480647T3 - Mono-ester eller asymmetrisk substituerede di-ester-prodrugs af dopamin-D1 receptoragonister - Google Patents

Mono-ester eller asymmetrisk substituerede di-ester-prodrugs af dopamin-D1 receptoragonister

Info

Publication number
DK1480647T3
DK1480647T3 DK03713475T DK03713475T DK1480647T3 DK 1480647 T3 DK1480647 T3 DK 1480647T3 DK 03713475 T DK03713475 T DK 03713475T DK 03713475 T DK03713475 T DK 03713475T DK 1480647 T3 DK1480647 T3 DK 1480647T3
Authority
DK
Denmark
Prior art keywords
dopamine
monoester
asymmetrically substituted
receptor agonists
ester prodrugs
Prior art date
Application number
DK03713475T
Other languages
Danish (da)
English (en)
Inventor
Hakan Wikstrom
Durk Dijkstra
Original Assignee
Darpharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0200478A external-priority patent/SE0200478D0/xx
Priority claimed from SE0200474A external-priority patent/SE0200474D0/xx
Application filed by Darpharma Inc filed Critical Darpharma Inc
Application granted granted Critical
Publication of DK1480647T3 publication Critical patent/DK1480647T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32Alcohol-abuse
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D221/00Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04Ortho- or peri-condensed ring systems
    • C07D221/18Ring systems of four or more rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03713475T 2002-02-15 2003-02-14 Mono-ester eller asymmetrisk substituerede di-ester-prodrugs af dopamin-D1 receptoragonister DK1480647T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0200478A SE0200478D0 (sv) 2002-02-15 2002-02-15 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine D1 receptor agonist A-86929
SE0200474A SE0200474D0 (sv) 2002-02-17 2002-02-17 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine D1 receptor agonists Dihydrexidine and Dinapsoline
PCT/US2003/004592 WO2003070245A1 (en) 2002-02-15 2003-02-14 Mono-ester and asymmetrically substituted di-ester pro-drugs of the dopamine d1 receptor agonists

Publications (1)

Publication Number Publication Date
DK1480647T3 true DK1480647T3 (da) 2009-01-26

Family

ID=27759833

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03713475T DK1480647T3 (da) 2002-02-15 2003-02-14 Mono-ester eller asymmetrisk substituerede di-ester-prodrugs af dopamin-D1 receptoragonister

Country Status (11)

Country Link
US (1) US7220754B2 (https=)
EP (1) EP1480647B1 (https=)
JP (1) JP2005526728A (https=)
AT (1) ATE406896T1 (https=)
AU (1) AU2003217430B2 (https=)
CA (1) CA2476115A1 (https=)
DE (1) DE60323339D1 (https=)
DK (1) DK1480647T3 (https=)
ES (1) ES2314189T3 (https=)
NO (1) NO20043634L (https=)
WO (1) WO2003070245A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9046537B2 (en) 2003-09-22 2015-06-02 Enzo Biochem, Inc. Method for treating inflammation by administering a compound which binds LDL-receptor-related protein (LRP) ligand binding domain
US20070155720A1 (en) * 2003-12-23 2007-07-05 Darpharma, Inc. Co-administration of dopamine-receptor binding compounds
US9052324B2 (en) 2004-05-19 2015-06-09 Enzo Biochem, Inc. Compounds and assays for controlling Wnt activity
US8596306B2 (en) * 2005-10-27 2013-12-03 Synthetic Gas Solutions, Llc Perfluorocarbon gas insufflation
WO2007098462A2 (en) * 2006-02-21 2007-08-30 Purdue Research Foundation Trans-fused chromenoisoquinolines, synthesis and methods for use
US9359303B2 (en) 2009-04-21 2016-06-07 Purdue Research Foundation Octahydrobenzoisoquinoline modulators of dopamine receptors and uses therefor
CA2890009C (en) * 2012-11-08 2017-11-28 Pfizer Inc. Heteroaromatic compounds and their use as dopamine d1 ligands

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4282227A (en) * 1980-05-22 1981-08-04 Smithkline Corporation Renal vasodilating 3,4-dihydroxyphenyltetrahydrothienopyridines
US4340600A (en) * 1980-05-22 1982-07-20 Smithkline Corporation Renal dilating methods and compositions using 4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinolines
JPH02138A (ja) * 1987-09-18 1990-01-05 Banyu Pharmaceut Co Ltd L‐ドーパ誘導体
US5047536A (en) * 1989-03-17 1991-09-10 Purdue Research Foundation Hexahydrobenzo(A)phenanthridine compounds
IE912999A1 (en) * 1990-09-07 1992-03-11 Abbott Lab Phenanthridine compounds
AU4391493A (en) * 1992-05-26 1993-12-30 Purdue Research Foundation Substituted-hexahydrobenzo(A)phenanthridines
ES2193158T3 (es) * 1993-04-06 2003-11-01 Abbott Lab Compuestos tetraciclicos agonistas de la dopamina.
JPH10502923A (ja) * 1994-07-15 1998-03-17 パーデュー・リサーチ・ファンデーション ジヒドレキシジンおよびその置換類似体の光学活性異性体
AU700688B2 (en) * 1995-08-18 1999-01-14 Purdue Research Foundation Novel fused isoquinolines as dopamine receptor ligands

Also Published As

Publication number Publication date
DE60323339D1 (de) 2008-10-16
JP2005526728A (ja) 2005-09-08
AU2003217430A1 (en) 2003-09-09
ATE406896T1 (de) 2008-09-15
US7220754B2 (en) 2007-05-22
EP1480647A4 (en) 2005-07-13
AU2003217430B2 (en) 2008-10-23
ES2314189T3 (es) 2009-03-16
US20050096469A1 (en) 2005-05-05
WO2003070245B1 (en) 2004-05-27
WO2003070245A1 (en) 2003-08-28
NO20043634L (no) 2004-11-11
EP1480647B1 (en) 2008-09-03
CA2476115A1 (en) 2003-08-28
EP1480647A1 (en) 2004-12-01

Similar Documents

Publication Publication Date Title
CR9587A (es) Derivados de piridazina
PA8621501A1 (es) Intermediarios de quinolina como inhibidores de receptores de tirosina quinasas y la síntesis de los mismos
AR056873A1 (es) Derivados de pirazolopirimidinas como inhibidores de quinasa dependientes de ciclina, composiciones farmaceuticas
AR021482A1 (es) Compuestos de 4-carboxiamino-1,2,3,4-tetrahidroquinolinas, composiciones farmaceuticas, kit, y uso de los mismos.
DK1682138T3 (da) Heterocykliske inhibitorer af MEK
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
NO20014759D0 (no) C(7)-estersubstituerte taksaner som antitumormidler
CR20140368A (es) Derivados y composiciones de isoindol 4´-0-sustituidos, composiciones que las comprenden y metodos de uso de los mismos (divisional 11036)
ES2081187T3 (es) Nuevas naftil-alquil-aminas, su procedimiento de preparacion y composiciones farmaceuticas que las contienen.
CA2495967A1 (fr) Nouveau procede de synthese et nouvelle forme cristalline de l'agomelatine ainsi que les compositions pharmaceutiques qui la contiennent
AR062211A1 (es) Derivados de 6-carboxi-normorfinano. composiciones farmaceuticas
ECSP088099A (es) Nuevos derivados de la 2-azetidinona para el tratamiento de enfermedades hiperlipidémicas
CO5680426A2 (es) 42-ester de rapamicina amorfo con acido 3-hidroxi-2-(hidroximetil)-2-metilpropionico y composiciones farmaceuticas que los contienen
CY1113395T1 (el) Σταθερη φαρμακευτικη συνθεση που περιεχει πυριμιδινη-σουλφαμιδη
AR064692A1 (es) Derivados de oxindol sustituido medicamentos que los comprenden y uso de los mismos
ECSP088229A (es) Derivados de pirazolona como inhibidores de 11-beta hsd1
AR072233A1 (es) Derivados de acido lipoico y composiciones farmaceuticas que los contienen y metodos para tratar una enfermedad
UY31885A (es) Derivados de las 1, 3, 5-triazina-2, 4-diaminas-6-sustituidas-n-sustituidas y sales farmacéuticamente aceptables de los mismos, composiciones y aplicaciones.
AR051089A1 (es) Compuestos de triazoloquinoleina y triazolonaftiridina sustituidas
EA200970266A1 (ru) Азабициклические соединения в качестве ингибиторов повторного поглощения моноаминов
DK1480647T3 (da) Mono-ester eller asymmetrisk substituerede di-ester-prodrugs af dopamin-D1 receptoragonister
CU20100157A7 (es) Nuevos derivados dihidroindolonas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
ATE468327T1 (de) Vr1-vanilloidrezeptorantagonisten mit einer iononischen unterstruktur
ATE240299T1 (de) Diester prodrugs von decahydroischinoline-3- carbonsäure
UY26298A1 (es) "derivados de bencimidazol sustituidos con aminocarbonilo, procedimientos para su preparación y su utilización como medicamentos."